Innovation in Hemophilia Therapies — “And Miles to Go, before [We] Sleep”

Albert Farrugia

doi:10.1055/s-0036-1597280

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2017; 43(01): 105-106
DOI: 10.1055/s-0036-1597280

Letter to the Editor

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Innovation in Hemophilia Therapies — “And Miles to Go, before [We] Sleep”

Autor*innen

Albert Farrugia

¹School of Surgery, QEII Medical Centre, The University of Western Australia, Western Australia, Australia

²Kedrion S.p.A, Via del Ciocco, Castelvecchio Pascoli, Lucca, Italy

Abstract

Volltext

Referenzen

References
1 Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost 2016; 42 (5) 513-517
2 Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII/factor IX products. Semin Thromb Hemost 2016; 42 (5) 518-525
3 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost 2016; 42 (5) 526-532
4 Kucab P, Stepanyan KD, Fugh-Berman A. Direct-to-consumer marketing to people with hemophilia. PLoS Med 2016; 13 (6) e1001996
5 Croteau SE, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia 2015; 21 (3) 285-288
6 Pasi J. A Subcutaneously Administered Investigational RNAi Therapeutic (Fitusiran) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B [Internet]. World Federation of Hemophilia Congress; 2016 Jul 25 [cited 2016 Aug 25]; Orlando, FL. Available from: http://www.alnylam.com/web/assets/WFH-2016_Fitusiran_Ph-1_072516_2.pdf . Accessed September 6, 2016
7 German Federal Joint Committee. Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Turoctocog alfa (Decision [Federal Joint Committee] of the Federal Joint Committee amending the Prescription Drug Guidelines (AM-RL): Appendix XII – Decisions on the benefit assessment of drugs with new active substances in accordance with § 35a SGB V [Social Security Code V] – Turoctocog Alfa) [Internet]. German Federal Joint Committee; 2014 Jun [cited 2016 Aug 25] p. 9. Report No.: BAnz AT 06.08.2014 B2. Available from: https://www.g-ba.de/downloads/39-261-2026/2014-07-03_AM-RL-XII_Turoctocog%20alfa_2014-01-15-D-092_BAnz.pdf . Accessed September 6, 2016
8 O'Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia 2015; 21 (4) 436-443
9 Market Research Bureau. Survey on Hemophilia Care & Price Monitoring United States [Internet]. Market Research Bureau; 2016 Jun [cited 2016 Aug 25] p. 182. Available from: http://marketingresearchbureau.com/list-of-reports/hemophilia-care-price-monitoring-wave-21-2/ . Accessed September 6, 2016
10 Coppola A, Tagliaferri A, Franchini M. Controversies in inherited bleeding disorders. Semin Thromb Hemost 2016; 42 (5) 459-462